Exelixis | EXEL - Ordinary Share Capital


Exelixis reported $248.88M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bayer EUR 982.42M 0 Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
Eisai JPY 282.46M 345K Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 248.88M 4.82M Jun/2026
Genmab DKK 61.44M 181K Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Puma Biotechnology USD 5K 0 Jun/2024
Sanofi EUR 1.2B 16.88M Mar/2026
Takeda JPY 1.58B 460K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Xencor USD 74.33M 265K Jun/2026